Valuation Metrics: A Closer Look
As of 18 Aug 2026, Ajanta Pharma’s P/E ratio stands at 41.02, a figure that positions the stock firmly in the very expensive category relative to its historical valuation and peer group. This is a significant increase from previous levels, signalling that investors are willing to pay a premium for the company’s earnings potential. The price-to-book value ratio has also escalated to 10.28, underscoring the market’s elevated expectations for the company’s asset utilisation and growth prospects.
Other valuation multiples reinforce this trend: the enterprise value to EBIT (EV/EBIT) ratio is 35.75, and the EV to EBITDA ratio is 31.45, both indicating a stretched valuation compared to industry norms. The EV to capital employed ratio at 11.19 and EV to sales at 7.99 further highlight the premium investors are attributing to Ajanta Pharma’s operational efficiency and revenue generation capabilities.
Peer Comparison: Contextualising Ajanta Pharma’s Valuation
When benchmarked against key peers in the Pharmaceuticals & Biotechnology sector, Ajanta Pharma’s valuation multiples stand out. For instance, Zydus Lifesciences is rated as attractive with a P/E of 22.89 and EV/EBITDA of 14.22, while Lupin is considered very attractive with a P/E of 17.33 and EV/EBITDA of 10.56. Even Mankind Pharma, which is categorised as expensive, has a higher P/E of 46.12 but a lower EV/EBITDA of 27.02 compared to Ajanta Pharma.
Other notable comparisons include Dr Reddy’s Labs with a fair valuation at a P/E of 30.88 and EV/EBITDA of 19.47, and Laurus Labs, which is very expensive with a P/E of 88.9 and EV/EBITDA of 48.97. Ajanta Pharma’s valuation, while high, is somewhat more moderate than Laurus Labs but still reflects a premium over most peers.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Financial Performance and Returns: Justifying the Premium?
Ajanta Pharma’s elevated valuation is supported by robust financial metrics and strong returns relative to the broader market. The company’s return on capital employed (ROCE) is an impressive 29.63%, while return on equity (ROE) stands at 23.33%, both indicators of efficient capital utilisation and profitability.
In terms of stock performance, Ajanta Pharma has outperformed the Sensex significantly across multiple time horizons. Year-to-date (YTD), the stock has delivered a 34.46% return compared to the Sensex’s negative 8.79%. Over one year, the stock’s return is 38.85% versus the Sensex’s -3.56%. Longer-term returns are even more striking, with a three-year gain of 109.19% against the Sensex’s 19.30%, and a five-year return of 141.11% compared to the Sensex’s 39.32%. Over a decade, Ajanta Pharma has appreciated by 189.72%, marginally outperforming the Sensex’s 177.55%.
Price Movement and Market Capitalisation
On 18 Aug 2026, Ajanta Pharma’s stock price closed at ₹3,725.00, up 1.36% from the previous close of ₹3,675.15. The stock traded within a range of ₹3,650.20 to ₹3,737.00, touching its 52-week high during the session. The company is classified as a mid-cap stock, reflecting its market capitalisation and growth profile within the Pharmaceuticals & Biotechnology sector.
Valuation Grade Upgrade and Market Sentiment
MarketsMOJO recently upgraded Ajanta Pharma’s mojo grade from Hold to Buy on 23 Mar 2026, reflecting improved sentiment and confidence in the company’s prospects. The mojo score currently stands at 71.0, signalling a favourable outlook. However, the valuation grade has shifted from expensive to very expensive, indicating that while the stock remains attractive, investors should be mindful of the premium being paid.
Implications for Investors
The shift in valuation parameters suggests that Ajanta Pharma is now trading at a premium relative to its historical averages and many peers. This premium is underpinned by strong financial performance, consistent returns, and positive market sentiment. Investors considering Ajanta Pharma should weigh the company’s growth potential and operational efficiency against the elevated multiples.
While the stock’s outperformance relative to the Sensex and sector peers is compelling, the very expensive valuation grade warrants caution. Prospective investors may want to monitor upcoming earnings releases and sector developments to assess whether the premium valuation is sustainable.
Thinking about Ajanta Pharma Ltd.? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this mid-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Conclusion: Balancing Growth and Valuation
Ajanta Pharma Ltd’s recent valuation shift to a very expensive rating reflects the market’s recognition of its strong fundamentals and superior returns. The company’s P/E and P/BV ratios, alongside other multiples, indicate a premium pricing relative to peers and historical levels. This premium is justified to an extent by Ajanta Pharma’s robust profitability metrics and consistent outperformance against the Sensex.
However, investors should remain vigilant given the stretched valuation, ensuring that future earnings growth and sector dynamics continue to support the current price levels. Ajanta Pharma remains a compelling mid-cap stock within the Pharmaceuticals & Biotechnology sector, but the elevated valuation calls for a balanced approach to investment decisions.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
